Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35
🏠 Home   ➤    Stock news

INVENTIVA Stock: Increase of 7.58% Over the Past Week

Inventiva's stock closed the week at €4.05, marking a 7.58% increase over the last five sessions. This performance significantly exceeds the gains of the CAC 40 (+1.13%) and the SBF 120 (+1.14%) over the same period. Over the year, the stock has risen by 85.55%.


INVENTIVA Stock: Increase of 7.58% Over the Past Week

Weekly Performance and Market Context

Inventiva's stock price settled at €4.05 at the last closing, marking a weekly increase of 7.58%. This growth occurs in a context where the main Parisian indices recorded more moderate gains, with +1.13% for the CAC 40 and +1.14% for the SBF 120. Over the past year, the performance reached 85.55%, highlighting a positive long-term dynamic for this biopharmaceutical stock listed on Euronext Growth. Trading was robust this week, reflecting a marked interest from traders in the stock. The resistance threshold is at €4.05, coinciding precisely with the closing price, while the key support is at €3.45. The one-month volatility stands at 11.90%, indicating moderate but regular movements. With a beta of -0.64, the stock shows a decorrelation from the market, often moving in the opposite direction of general trends. The 50-day moving average is at €3.58 and the 200-day at €3.42, levels that the price currently exceeds clearly. These technical elements confirm a favorable position relative to medium and long-term trends.

Technical Analysis Insights

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Technical analysis highlights several indicators aligned with an upward dynamic. The MACD line is at 0.11, signaling positive momentum. The RSI at 63 indicates a neutral to bullish situation, with no imminent signs of overbuying. The Bollinger Bands place the price at the upper limit at €4.05, while the lower band is at €3.42, thus framing recent fluctuations. The price moves above the 50-day moving average (€3.58) and the 200-day moving average (€3.42), confirming an upward trend in the medium and long term. These moving averages serve as potential supports in case of a pullback. Controlled volatility at 11.90% over a month allows for smooth movements without excess. The negative beta of -0.64 highlights the stock's independence from broad market movements, an asset in an uncertain environment. This technical configuration reflects a week of positive consolidation for Inventiva, with the price testing the resistance threshold at €4.05. Momentum indicators such as the MACD and RSI support this development, while the Bollinger Bands define a clear trading channel.

Market Outlook in Early 2026

In a slightly progressing Parisian market at the start of 2026, Inventiva stands out with its ability to outperform. The CAC 40 targets 8,200 points at the opening, after a positive year in 2025. The stock, with its annual performance of 85.55%, fits into this optimistic trend of growth stocks. The technical thresholds to watch remain the support at €3.45 and the resistance at €4.05, framing the immediate prospects.



Sector Santé · Biotechnologies · Pharmacie Biotechnologie


Assurance vie

Context

Period
  • Period: 9M 2025
Guidance from the release
  • Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
  • Besoin de capitaux supplémentaires pour financer les opérations
  • Risque que la Société utilise ses ressources plus rapidement que prévu
  • Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
  • Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
  • Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
  • Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
  • Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
  • Résultats principaux de l’essai NATiV3 attendus au second semestre 2026

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit